These studies indicated that the presence of co-occurring genetic events and the mutant KRAS allelic content increase biological heterogeneities of KRAS-mutant NSCLC, which complicates the treatment of KRAS-mutant lung cancers. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.